All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Arlo-Cel Demonstrates Tolerability, Efficacy in R/R Myeloma

September 19th 2025

Arlo-cel given as a single infusion drove efficacy and was safe in relapsed/refractory multiple myeloma.

D-VRd Produces Favorable PROs and Safety Outcomes in MRD-Negative Newly Diagnosed Multiple Myeloma

September 19th 2025

D-VRd led to favorable PRO outcomes in patients with newly diagnosed multiple myeloma who had MRD negativity after therapy.

Taletrectinib Wins Japanese Approval for ROS1+ Advanced NSCLC

September 19th 2025

Taletrectinib was approved in Japan for advanced non–small cell lung cancer harboring ROS1 fusions.

Pembrolizumab Earns 2 Positive CHMP Opinions in HNSCC, Other EU Indications

September 19th 2025

The EMA’s CHMP has recommended the approval of subcutaneous pembrolizumab across all indications and perioperative pembrolizumab in locally advanced HNSCC.

Maintenance Belantamab Mafodotin Plus Pomalidomide/Dexamethasone Produces Responses in High-Risk Myeloma

September 19th 2025

Maintenance therapy with belantamab mafodotin, pomalidomide, and dexamethasone was safe and led to durable responses in high-risk myeloma.

CHMP Recommends EU Approval of Subcutaneous Mosunetuzumab in R/R Follicular Lymphoma

September 19th 2025

The CHMP has recommended the European approval of subcutaneous mosunetuzumab in relapsed/refractory follicular lymphoma.

Orca-T Delivers Major Gains Beyond Conventional Prophylaxis in Hematologic Malignancies

September 19th 2025

David Miklos, MD, PhD, discusses the potential role for Orca-T vs standard PTCy after allogeneic transplant in hematologic malignancies.

MD Anderson and Phoenix SENOLYTIX Announce Strategic Cross-Licensing Agreement to Enhance Inducible Switch Technologies for Cell and Gene Therapies

September 19th 2025

The global cross-licensing agreement will facilitate work aimed at enhancing the development of inducible switch technologies for cell and gene therapies.

Iberdomide/Daratumumab/Dexamethasone Is Effective in Newly Diagnosed Multiple Myeloma

September 18th 2025

Iberdomide plus daratumumab and dexamethasone yielded deep responses and had a manageable safety profile in transplant-ineligible multiple myeloma.

Fixed-Duration Cevostamab After CAR T-Cell Therapy Is Well Tolerated in Heavily Pretreated Myeloma

September 18th 2025

Data from a phase 2 study suggested that fixed-duration cevostamab is both feasible and safe in patients with heavily pretreated multiple myeloma.

Linvoseltamab Plus Carfilzomib Is Safe, Feasible, and Elicits Durable Responses in R/R Myeloma

September 18th 2025

Linvoseltamab plus carfilzomib produced expected toxicities in patients with heavily pretreated, relapsed/refractory multiple myeloma.

Daratumumab-Based Regimens Yield Clinical Benefit Irrespective of Frailty Changes in Newly Diagnosed, Transplant-Ineligible Myeloma

September 18th 2025

Post hoc data demonstrated benefit with daratumumab-based regimens in newly diagnosed, transplant-ineligible myeloma, regardless of frailty changes.

Winship Launches Mobile Prostate Cancer Screening Program to Tackle Disparities, Improve Access

September 18th 2025

Winship Cancer Institute of Emory University has launched a mobile prostate cancer screening program.

Isa-KRd Leads to MRD Negativity in Subgroups of High-Risk Newly Diagnosed Multiple Myeloma

September 18th 2025

Isa-KRd led to a 74.8% MRD negativity rate in high-risk newly diagnosed multiple myeloma subgroups.

Path Toward Accelerated Approval of RP1 in Advanced Melanoma Remains Unclear After FDA Type A Meeting

September 18th 2025

Replimune completed a Type A meeting with the FDA following a complete response letter for RP1 in advanced melanoma.

European Commission Green-Lights Vimseltinib for Symptomatic, Unresectable TGCT

September 18th 2025

Vimseltinib earned approval from the European Commission for the treatment of symptomatic, unresectable tenosynovial giant cell tumors.

Targeted Therapies Drive Demand for Comprehensive Biomarker Testing in NSCLC

September 18th 2025

Lung cancer experts share the evolution of biomarker testing that has led to advances in patient selection for treatment, as well as challenges that future developments may address.

Advances in Surgical Approaches and Targeted Therapies Highlight Progress in Uterine Cancer

September 18th 2025

John P. Diaz, MD, discusses the role of minimally invasive surgical approaches for the treatment of patients with uterine cancer.

SHR-4849 Shows Preliminary Activity With Manageable Safety in Relapsed Small Cell Lung Cancer

September 18th 2025

SHR-4849 showed acceptable safety and early antitumor activity in relapsed small cell lung cancer.

SHR-4849 Shows Activity With Manageable Safety in Relapsed Small Cell Lung Cancer

September 18th 2025

SHR-4849 showed acceptable safety and preliminary antitumor activity in relapsed small cell lung cancer.